Bio Honey: How Much Runway Did The 2025 Cash Raise Really Buy
Bio Honey's 2025 rights issue bought much more than 12 months of runway in a mechanical reading, but that runway rested on a lean transition year and on an additional funding layer already embedded in the warrants. The gap between the arithmetic and the filing's conservative wording is the core of the story.
The main article correctly identified the big balance-sheet shift at Bio Honey in 2025. The rights issue pulled the company out of a tight-cash position and gave it real breathing room. But that still does not answer the more important question: how much time did that move really buy, and what capital cost was merely pushed into the next layer.
To answer that, the filing has to be split into three different layers: the cash that already came in, the cash burn that actually showed up in 2025, and the extra financing layer that was still tied to the warrants through February 26, 2026. Once those three layers are separated, the picture becomes much sharper: year-end 2025 looks like far more than a 12-month runway if one simply extrapolates 2025, but 2025 was still too lean a transition year to treat that math as a promise.
The 2025 Cash Bridge
On a total-liquidity basis, meaning cash plus deposits, Bio Honey started 2025 with about NIS 4.856 million and ended it with about NIS 9.514 million. That jump did not come from a dramatic improvement in cash burn. It came mainly from a NIS 9.081 million net financing inflow from the May 2025 raise. Against that stood fairly clean uses of cash: NIS 3.912 million consumed by operating activities, NIS 500 thousand invested in Wilk, and another NIS 11 thousand of reported capex. That makes the 2025 bridge unusually readable.
The mechanical reading of that bridge is generous. If the year-end liquidity balance of about NIS 9.514 million is divided only by 2025 operating cash burn, the result is roughly 29 months of runway. If the frame is tightened into all-in cash flexibility, meaning the Wilk investment and reported capex are also included, the result is still roughly 26 months. In both cases the number is far longer than the conservative wording in note 1(e), where the company states in the annual report published on February 19, 2026 that its cash and cash equivalents should allow it to continue operating for the next 12 months.
| Runway frame | Calculation base | Result | What it misses |
|---|---|---|---|
| Mechanical operating-cash reading | 9.514 divided by 3.912 | About 29 months | Assumes 2026 and 2027 will look like 2025 |
| 2025 all-in reading | 9.514 divided by 4.423 | About 26 months | Still rests on a transition year before routine production |
| The company's audited framing | Note 1(e) | 12 months | This is the conservative reading that bakes in operating and financing uncertainty |
The gap between roughly 26 to 29 months in the arithmetic and 12 months in the audited wording is not a contradiction. It is the point of the analysis. The 2025 numbers say the raise bought real time. The company's own wording says it is not prepared to guarantee that the move from pilot to routine production will cost what 2025 cost.
Why 2025 Looks Longer Than It Really Is
The first yellow flag is that the bottom line improved more than cash burn did. Net loss fell to NIS 3.910 million, but cash used in operating activities barely moved from 2024 and stayed near NIS 3.9 million. The reason is straightforward: 2025 benefited from NIS 963 thousand of net finance income, including NIS 314 thousand of deposit interest and NIS 728 thousand from the fair-value remeasurement of the Wilk investment. Only the interest line actually turned into cash, and even that existed because the raise proceeds were sitting in the bank. So the cleaner net loss says less about core economics and more about the fact that the company suddenly had cash that could earn interest.
The second yellow flag is that 2025 no longer carried the old Rehovot lease burden. In 2024 the company terminated its lab and office lease early, booked a NIS 700 thousand obligation to be paid over 56 installments, and by 2025 the cash flow statement no longer showed lease payments. That matters because anyone who projects the 2025 burn rate forward is looking at a year in which liquidity already benefited from the exit from the old lease arrangement.
The third yellow flag is the cost base itself. R&D expense fell to NIS 1.701 million, mainly because payroll dropped after the former VP of R&D left in the second half of 2025. At the same time, general and administrative expense rose to NIS 3.172 million, mainly because the company now carried a permanent CEO cost. By the end of 2025 this was still a very lean company, with only four employees and service providers in total, including two in R&D and regulation and two in management and finance. This is still not the cost shape of a routine production and sales company. It is the cost shape of a company that is still building the transition.
2025 was a bridge year: less lab, more management, more cash in the bank, and still no revenue. That is why the backward-looking runway appears long, but it rests on a year that still did not carry the full cost of routine production, marketing, regulation, and distribution that the company itself is trying to move into in 2026.
Dilution Did Not End With The Raise, It Was Pushed Into The Warrant Layer
To understand what the 2025 cash balance really bought, the equity cost that has already been paid also has to be put on the table. On May 29, 2025 the company issued 6,507,395 ordinary shares and 6,507,395 Series 1 warrants and raised about NIS 9.1 million gross. That means the share layer of the raise alone equaled almost 75% of the year-end 2024 issued share base, which stood at 8,691,191 shares. This is not a footnote. The runway purchased in 2025 was already funded through a very aggressive expansion of the equity base.
The second layer sits right behind it. The warrants issued in May 2025 were exercisable through February 26, 2026 at an exercise price of NIS 1.8 per warrant. In theory, if they had all been exercised, the company could have received another roughly NIS 11.7 million gross and issued another 6.507 million shares. Relative to the 15.309 million shares issued and paid at the end of 2025, that implies another roughly 42.5% of potential dilution. So the next financing layer in the annual report was not bank debt or credit. It was conditional equity financing already embedded in the capital structure.
One more point matters here: this layer did not really disperse control. Controlling shareholder Ari Stiematzky participated in the rights issue and by the end of 2025 held 66.16% of the issued and paid-up share capital, along with 5,064,355 Series 1 warrants that put him at 68.40% on a fully diluted basis. That matters because it means the next possible funding layer remained tied to the control anchor rather than reopening the capital structure in any meaningful way.
The incentive structure also reminds the reader that this is not "free" capital. The May 2025 raise itself entitled the CEO to a NIS 172 thousand cash bonus, and over the full year the company recorded NIS 657 thousand of share-based compensation expense. That is not a criticism of the incentive plan. It is simply a reminder that in a pre-revenue company, financing, control, and management compensation are much more tightly linked than they are in a company that already sells.
What This Means For The Move From Pilot To Routine Production
The key point is that the 2025 cash balance bought time, but it did not remove the need for another financing test. The company itself says it is still trying to move from R&D into commercial and industrial feasibility, which includes routine commercial production, regulatory completion in Israel and the US, and first sales. In the same filing it also says it holds raw-material inventory sufficient for several tons of production and intends to place additional raw-material orders. This is exactly the point where the 2025 runway stops being too comfortable an anchor: the move from a successful pilot to routine commercial activity requires more working capital, more execution, and probably more spending, all before recurring revenue exists.
That is why the answer to the question of how much runway the 2025 cash raise really bought is two-layered. On a pure 2025 basis, much more than one year, closer to something above two years. On the basis of the next stage the company is trying to enter, routine production, regulation, and first sales, the conservative 12-month reading looks more reasonable. What the rights issue bought was not a solution. It bought the right to try.
That also explains why the 2026 to 2027 test will not be only about the cash balance itself. It will be a test of funding quality. If the existing-plant model, the regulatory work, and early distribution activity start turning into revenue, then 2025 dilution will look like a reasonable transition cost. If not, the market may conclude that the stronger cash balance bought time, but also merely pushed the company toward another round of dilution or another funding path tied to control.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.